|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.63 USD | -1.87% |
|
-9.93% | +164.98% |
| Apr. 18 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
| Mar. 06 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
On January 30, 2019, Rezolute, Inc. (OTCPK:RZLT) closed the transaction. The company amended the terms of the transaction. The company issued 1,250,000 shares to each of the investors for $10 per share.
Each investor invested $12,500,000 in the transaction.
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 13,650 KRW | 0.00% | -0.29% | 138M | ||
| 7,120 KRW | +0.85% | -7.89% | 216M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +164.98% | 108M | |
| +7.38% | 111B | |
| +11.13% | 106B | |
| -12.46% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.79% | 16.81B | |
| +37.54% | 12.54B | |
| -24.36% | 8.09B |
REZOLUTE, INC. 
